# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Wells Fargo analyst Stephen Baxter maintains McKesson (NYSE:MCK) with a Equal-Weight and lowers the price target from $576 t...
Citigroup analyst Daniel Grosslight maintains McKesson (NYSE:MCK) with a Buy and lowers the price target from $670 to $630.
Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by Geron...
Leerink Partners analyst Michael Cherny maintains McKesson (NYSE:MCK) with a Outperform and lowers the price target from $67...
- SEC Filing
McKesson Canada will continue to own and operate Rexall and Well.ca until transaction close, which is subject to customary clos...